1. 96PAXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts). (23rd October 2018) Authors: Cardone, C; Blauensteiner, B; Moreno-Viedma, V; Paul, M C; Martini, G; Vitiello, P P; Ciardiello, D; Borrelli, C; Poliero, L; Vitale, P; Zanaletti, N; Famiglietti, V; Rachiglio, A M; Rizzi, D; Maiello, E; Latiano, T P; Normanno, N; Sibilia, M; Ciardiello, F; Martinelli, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. (7th August 2017) Authors: Normanno, N; Esposito Abate, R; Lambiase, M; Forgione, L; Cardone, C; Iannaccone, A; Sacco, A; Rachiglio, A M; Martinelli, E; Rizzi, D; Pisconti, S; Biglietto, M; Bordonaro, R; Troiani, T; Latiano, T P; Giuliani, F; Leo, S; Rinaldi, A; Maiello, E; Ciardiello, F Journal: Annals of oncology Issue: Volume 29:Number 1(2018) Page Start: 112 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗